Shitang Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shitang Ma has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Aimin Sheng
Life and Health College, Anhui Science and Technology University, Fengyang, China
1 shared publicationHaihua Shang
Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, Tianjin, China
1 shared publicationJiawen Wang
Shanghai
1 shared publicationLeyuan Ji
College of Traditional Chinese Medicine, Anhui University of Chinese Medicine, Hefei, China
1 shared publication- Maoliang Liao
College of Biological and Pharmaceutical Engineering, West Anhui University, Lu’an, China
1 shared publication Ning Zhang
Fengyang
1 shared publication
Latest Publications
- Open Access
- 3 December 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1714907
Preparation and biomedical application of light-responsive hydrogels based on natural products
This article systematically reviews the light-responsive hydrogels based on natural products, with a focus on their extensive applications in the field of biomedicine. Regarding the preparation methods, the article elaborates on the physical self-assembly, chemical crosslinking agent method, photocrosslinking method, and free radical polymerization method. The biomedical application section introduces their applications in drug release and wound healing based on the mechanisms of photochemical reactions, photoisomerization reactions, and photothermal reactions. In terms of quality evaluation frameworks, the natural light-responsive hydrogels evaluation frameworks is summarized, and the shortcomings of the existing evaluation frameworks are analyzed. Finally, the article summarizes its application potential and development bottlenecks, looks forward to future research directions, and proposes targeted development suggestions, thereby promoting its wider applications in deep disease treatment and personalized medicine.
- 3 December 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1714907
Open AccessPreparation and biomedical application of light-responsive hydrogels based on natural products
This article systematically reviews the light-responsive hydrogels based on natural products, with a focus on their extensive applications in the field of biomedicine. Regarding the preparation methods, the article elaborates on the physical self-assembly, chemical crosslinking agent method, photocrosslinking method, and free radical polymerization method. The biomedical application section introduces their applications in drug release and wound healing based on the mechanisms of photochemical reactions, photoisomerization reactions, and photothermal reactions. In terms of quality evaluation frameworks, the natural light-responsive hydrogels evaluation frameworks is summarized, and the shortcomings of the existing evaluation frameworks are analyzed. Finally, the article summarizes its application potential and development bottlenecks, looks forward to future research directions, and proposes targeted development suggestions, thereby promoting its wider applications in deep disease treatment and personalized medicine.
- Open Access
- 19 January 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11
Emodin Inhibits the Proliferation of MCF-7 Human Breast Cancer Cells Through Activation of Aryl Hydrocarbon Receptor (AhR)
Natural products have proved to be a promising source for the development of potential anticancer drugs. Emodin, a natural compound from Rheum palmatum, is used to treat several types of cancers, including lung, liver, and pancreatic. However, there are few reports regarding its use in the treatment of breast cancer. Thus, the therapeutic effect and mechanism of emodin on MCF-7 human breast cancer cells were investigated in this study. Morphological observations and cell viability were evaluated to determine the anti-proliferation activity of emodin. Network pharmacology and molecular docking were performed to screen the potential targets. Western blot analysis was used to explore a potential antitumor mechanism. The results showed that emodin (50–100 μmol/L) could significantly inhibit the proliferation of MCF-7 cells in a time and dose-dependent manner. Furthermore, virtual screening studies indicated that emodin was a potent aryl hydrocarbon receptor (AhR) agonist in chemotherapy for breast cancer. Finally, when MCF-7 cells were treated with emodin (100 μmol/L) for 24 h, the AhR and cytochrome P450 1A1 (CYP1A1) protein expression levels were significantly upregulated compared with the control group. Our study indicated that emodin exhibited promising antitumor activity in MCF-7 cells, likely through activation of the AhR-CYP1A1 signaling pathway. These findings lay a foundation for the application of emodin in breast cancer treatment.
- 19 January 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11
Open AccessEmodin Inhibits the Proliferation of MCF-7 Human Breast Cancer Cells Through Activation of Aryl Hydrocarbon Receptor (AhR)
Natural products have proved to be a promising source for the development of potential anticancer drugs. Emodin, a natural compound from Rheum palmatum, is used to treat several types of cancers, including lung, liver, and pancreatic. However, there are few reports regarding its use in the treatment of breast cancer. Thus, the therapeutic effect and mechanism of emodin on MCF-7 human breast cancer cells were investigated in this study. Morphological observations and cell viability were evaluated to determine the anti-proliferation activity of emodin. Network pharmacology and molecular docking were performed to screen the potential targets. Western blot analysis was used to explore a potential antitumor mechanism. The results showed that emodin (50–100 μmol/L) could significantly inhibit the proliferation of MCF-7 cells in a time and dose-dependent manner. Furthermore, virtual screening studies indicated that emodin was a potent aryl hydrocarbon receptor (AhR) agonist in chemotherapy for breast cancer. Finally, when MCF-7 cells were treated with emodin (100 μmol/L) for 24 h, the AhR and cytochrome P450 1A1 (CYP1A1) protein expression levels were significantly upregulated compared with the control group. Our study indicated that emodin exhibited promising antitumor activity in MCF-7 cells, likely through activation of the AhR-CYP1A1 signaling pathway. These findings lay a foundation for the application of emodin in breast cancer treatment.